High-dose interleukin-2 can prompt t cells to eradicate cancer in 10-20% of patients with metastatic melanoma or renal cell cancer.

“there's another subset of patients typically with cancers like melanoma and renal cell cancer which have a high mutagenic burden where they might not have enough immune cells to recognize and kill the cancer completely without any prompting but if you prompt them with a cytokine like interleukin 2 at a very high dose that is sufficient for their t cells to go and eradicate the cancer to put that number in context we're talking about 10 to 20 percent of people with metastatic melanoma or renal or renal cell cancer will respond to that”